CEL-SCI Corporation (CVM)
收市後：
| 前收市價 | 1.5000 |
| 開市 | 1.5400 |
| 買盤 | 1.5200 x 800 |
| 賣出價 | 1.5700 x 800 |
| 今日波幅 | 1.5000 - 1.5700 |
| 52 週波幅 | 1.0400 - 3.2300 |
| 成交量 | |
| 平均成交量 | 315,204 |
| 市值 | 84.208M |
| Beta 值 (5 年，每月) | 1.17 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -0.6900 |
| 業績公佈日 | 2024年5月10日 - 2024年5月14日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 1996年8月28日 |
| 1 年預測目標價 | 8.47 |
Insider Monkey12 Best Day Trading Stocks To Buy
In this article, we discuss the 12 best day trading stocks to buy. If you want to read about some more day trading stocks, go directly to 5 Best Day Trading Stocks To Buy. Over the past few years, the rise of a new generation of stock traders that like to engage in risky bets, […]
BenzingaWhy CEL-SCI Shares Are Shooting Higher Today
CEL-SCI Corporation (NYSE: CVM) announced that the latest results from its pivotal Phase 3 study of Multikine, a presurgical cancer immunotherapy, were presented at the European Society for Radiotherapy and Oncology (ESTRO) 2023 Congress. CEL-SCI's IT-MATTERS Phase 3 study reported a statistically significant 14.1% absolute 5-year overall survival benefit in the intent-to-treat (ITT) subjects who were categorized as a lower risk to recurrence (LR) and received Multikine followed by surgery and r
